ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.
Company profile
Ticker
LGND
Exchange
Website
CEO
John Higgins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LIGAND PHARMACEUTICALS
SEC CIK
Corporate docs
Subsidiaries
LIGAND PHARMACEUTICALS INCORPORATED • Allergan Ligand Retinoid Therapeutics, Inc. • Aramed Inc. • Cita NeuroPharmaceuticals Inc. • CyDex Pharmaceuticals, Inc. • LHNC, Inc. • Ligand Holdings UK Limited • Ligand JVR, Inc. • Ligand Pharmaceuticals International, Inc. • Ligand UK Development Limited ...
IRS number
770160744
LGND stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
19 Apr 24
S-8
Registration of securities for employees
1 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Other Events
5 Jan 24
8-K
Entry into a Material Definitive Agreement
1 Dec 23
8-K/A
Ligand Reports Third Quarter 2023 Financial Results
9 Nov 23
Transcripts
LGND
Earnings call transcript
2023 Q4
27 Feb 24
LGND
Earnings call transcript
2023 Q3
8 Nov 23
LGND
Earnings call transcript
2023 Q2
8 Aug 23
LGND
Earnings call transcript
2023 Q1
4 May 23
LGND
Earnings call transcript
2022 Q4
22 Feb 23
LGND
Earnings call transcript
2022 Q3
8 Nov 22
LGND
Earnings call transcript
2022 Q2
9 Aug 22
LGND
Earnings call transcript
2022 Q1
4 May 22
LGND
Earnings call transcript
2021 Q4
18 Feb 22
LGND
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
4
Todd C Davis
27 Mar 24
4
Stephen L Sabba
7 Mar 24
4
Jason Aryeh
6 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
4
Andrew Reardon
29 Feb 24
4
Matthew E Korenberg
29 Feb 24
4
Octavio Espinoza
29 Feb 24
4
Todd C Davis
29 Feb 24
144/A
Notice of proposed sale of securities (amended)
29 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.86 mm | 19.86 mm | 19.86 mm | 19.86 mm | 19.86 mm | 19.86 mm |
Cash burn (monthly) | 2.86 mm | (no burn) | 4.05 mm | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 19.71 mm | n/a | 27.87 mm | n/a | n/a | n/a |
Cash remaining | 149.73 k | n/a | -8.01 mm | n/a | n/a | n/a |
Runway (months of cash) | 0.1 | n/a | -2.0 | n/a | n/a | n/a |
Institutional ownership, Q3 2023
87.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 191 |
Opened positions | 22 |
Closed positions | 28 |
Increased positions | 64 |
Reduced positions | 73 |
13F shares | Current |
---|---|
Total value | 916.18 bn |
Total shares | 15.43 mm |
Total puts | 22.70 k |
Total calls | 51.30 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 2.84 mm | $170.24 bn |
Vanguard | 1.85 mm | $110.96 bn |
JHG Janus Henderson | 1.34 mm | $80.40 bn |
MCQEF Macquarie | 991.82 k | $59.43 bn |
STT State Street | 623.26 k | $37.35 bn |
Dimensional Fund Advisors | 614.39 k | $36.82 bn |
Stephens Investment Management | 467.56 k | $28.02 bn |
Villere ST Denis J & Co | 438.16 k | $26.25 bn |
Chicago Capital | 360.35 k | $21.59 bn |
Geode Capital Management | 352.62 k | $21.13 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Davis Todd C | Common Stock | Option exercise | Acquire M | No | No | 66.19 | 3,556 | 235.37 k | 120,160 |
25 Mar 24 | Davis Todd C | Common Stock | Option exercise | Acquire M | No | No | 68.51 | 2,156 | 147.71 k | 116,604 |
25 Mar 24 | Davis Todd C | Common Stock | Option exercise | Acquire M | No | No | 67.24 | 2,855 | 191.97 k | 114,448 |
25 Mar 24 | Davis Todd C | Common Stock | Option exercise | Acquire M | No | No | 46.2 | 7,448 | 344.10 k | 111,593 |
25 Mar 24 | Davis Todd C | NQSO Common Stock | Option exercise | Dispose M | No | No | 68.51 | 2,156 | 147.71 k | 0 |
25 Mar 24 | Davis Todd C | NQSO Common Stock | Option exercise | Dispose M | No | No | 67.24 | 2,855 | 191.97 k | 0 |
25 Mar 24 | Davis Todd C | NQSO Common Stock | Option exercise | Dispose M | No | No | 66.19 | 3,556 | 235.37 k | 0 |
25 Mar 24 | Davis Todd C | NQSO Common Stock | Option exercise | Dispose M | No | No | 46.2 | 7,448 | 344.10 k | 0 |
5 Mar 24 | Aryeh Jason | Common Stock | Option exercise | Acquire M | No | No | 39.35 | 2,893 | 113.84 k | 74,422 |
5 Mar 24 | Aryeh Jason | NQSO Common Stock | Option exercise | Dispose M | No | No | 39.35 | 2,893 | 113.84 k | 0 |
News
Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $95 Price Target
12 Apr 24
Ligand Pharmaceuticals Announces Topiramate Injection Data At 9th London-Innsbruck Colloquium On Status Epilepticus And Acute Seizures Conference
8 Apr 24
Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of ZELSUVMI, Scott Plesha Named CEO
3 Apr 24
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $144 Price Target
29 Feb 24
Why Is Ligand Pharmaceuticals Stock Trading Higher Today?
27 Feb 24
Press releases
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
8 Apr 24
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
3 Apr 24
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
5 Mar 24
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Mar 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24